{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:43:29Z","timestamp":1791546209346,"version":"4.3.4"},"reference-count":147,"publisher":"Impact Journals, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,2,28]]},"DOI":"10.18632\/oncotarget.14109","type":"journal-article","created":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T14:25:59Z","timestamp":1482848759000},"page":"16052-16074","source":"Crossref","is-referenced-by-count":277,"title":["Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application"],"prefix":"10.18632","volume":"8","author":[{"given":"Young Kwang","family":"Chae","sequence":"first","affiliation":[{"name":"Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"},{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthi","family":"Ranganath","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Hammerman","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Vaklavas","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, University of Alabama Birmingham, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Mohindra","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"},{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Kalyan","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"},{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Matsangou","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"},{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Costa","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedito","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"},{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M.","family":"Villaflor","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"},{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"},{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA"},{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,12,22]]},"reference":[{"issue":"40","key":"1","doi-asserted-by":"crossref","first-page":"25049","DOI":"10.1074\/jbc.271.40.25049","article-title":"Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains","volume":"271","author":"Friesel","year":"1996","journal-title":"J Biol Chem"},{"issue":"4","key":"2","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1073\/pnas.88.4.1095","article-title":"Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3","volume":"88","author":"Hayman","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"3","first-page":"2303","article-title":"Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation","volume":"7","author":"Herlyn","year":"1992","journal-title":"Oncogene"},{"issue":"1","key":"4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/bbrc.1997.7588","article-title":"Basic fibroblast growth factor induces apoptosis in myofibroblastic cells isolated from rat palatal mucosa","volume":"240","author":"Kuroda","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"5","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1073\/pnas.89.8.3315","article-title":"FDC-P1 myeloid cells engineered to express fibroblast growth factor receptor 1 proliferate and differentiate in the presence of fibroblast growth factor and heparin","volume":"89","author":"Bernard","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"6","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"7","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1053\/j.seminoncol.2011.01.018","article-title":"Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors","volume":"38","author":"Demetri","year":"2011","journal-title":"Semin Oncol"},{"issue":"11","key":"8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Norton","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jmb.2004.04.031","article-title":"Towards a resolution of the stoichiometry of the fibroblast growth factor (FGF)-FGF receptor-heparin complex","volume":"339","author":"Blundell","year":"2004","journal-title":"J Mol Biol"},{"issue":"3","key":"10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives","volume":"3","author":"Soria","year":"2013","journal-title":"Cancer Discov"},{"issue":"4","key":"11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0888-7543(91)90041-C","article-title":"A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4","volume":"11","author":"Wasmuth","year":"1991","journal-title":"Genomics"},{"issue":"1","key":"12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/MCB.12.1.82","article-title":"Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities","volume":"12","author":"Williams","year":"1992","journal-title":"Mol Cell Biol"},{"issue":"10","key":"13","first-page":"1957","article-title":"Promoter region of the murine fibroblast growth factor receptor 2 (bek\/KGFR) gene","volume":"7","author":"Givol","year":"1992","journal-title":"Oncogene"},{"issue":"2","key":"14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0378-1119(01)00518-2","article-title":"Identification of a new fibroblast growth factor receptor, FGFR5","volume":"271","author":"Murison","year":"2001","journal-title":"Gene"},{"issue":"2","key":"15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/geno.2000.6332","article-title":"Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors","volume":"69","author":"Trueb","year":"2000","journal-title":"Genomics"},{"issue":"6","key":"16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00018-010-0576-3","article-title":"Biology of FGFRL1, the fifth fibroblast growth factor receptor","volume":"68","author":"Trueb","year":"2011","journal-title":"Cell Mol Life Sci"},{"issue":"33","key":"17","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/sj.onc.1203726","article-title":"Fibroblast growth factor (FGF) signaling through PI 3-kinase and Akt\/PKB is required for embryoid body differentiation","volume":"19","author":"Lonai","year":"2000","journal-title":"Oncogene"},{"key":"18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/mcne.1996.0049","article-title":"CAM-FGF Receptor Interactions: A Model for Axonal Growth","volume":"8","author":"Walsh","year":"1996","journal-title":"Mol Cell Neurosci"},{"issue":"29","key":"19","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1038\/sj.onc.1203650","article-title":"Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4","volume":"19","author":"Donoghue","year":"2000","journal-title":"Oncogene"},{"issue":"7","key":"20","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1083\/jcb.141.7.1647","article-title":"Activation of the MAP kinase pathway by FGF-1 correlates with cell proliferation induction while activation of the Src pathway correlates with migration","volume":"141","author":"Maciag","year":"1998","journal-title":"J Cell Biol"},{"issue":"12","key":"21","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR Signaling in Cancer","volume":"21","author":"Soria","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/annonc\/mdt419","article-title":"Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors","volume":"25","author":"Tabernero","year":"2014","journal-title":"Ann Oncol"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Helsten, Elkin, Arthur, Tomson, Carter, Kurzrock. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2015.","DOI":"10.1158\/1078-0432.CCR-14-3212"},{"issue":"19","key":"24","first-page":"4360","article-title":"Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups","volume":"57","author":"Theillet","year":"1997","journal-title":"Cancer Res"},{"issue":"1","key":"25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2013.10.004","article-title":"High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer","volume":"83","author":"Birner","year":"2014","journal-title":"Lung Cancer"},{"issue":"22","key":"26","doi-asserted-by":"crossref","first-page":"8645","DOI":"10.1158\/0008-5472.CAN-09-1576","article-title":"The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo","volume":"69","author":"Seckl","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.oraloncology.2006.01.005","article-title":"Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC)","volume":"43","author":"Joos","year":"2007","journal-title":"Oral Oncol"},{"issue":"16","key":"28","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1158\/1078-0432.CCR-07-0502","article-title":"High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications","volume":"13","author":"Campbell","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"11","key":"29","first-page":"4514","article-title":"High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer","volume":"61","author":"Simon","year":"2001","journal-title":"Cancer Res"},{"issue":"6","key":"30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/gcc.20655","article-title":"Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development","volume":"48","author":"Missiaglia","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"31","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1158\/1078-0432.CCR-06-2555","article-title":"DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma","volume":"13","author":"Bloemena","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1096-9896(199604)178:4<429::AID-PATH495>3.0.CO;2-1","article-title":"Immunohistochemical study of overexpression of fibroblast growth factor-1 (FGF-1), FGF-2, and FGF receptor-1 in human malignant salivary gland tumours","volume":"178","author":"Takada","year":"1996","journal-title":"J Pathol"},{"issue":"15","key":"33","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/cncr.29401","article-title":"Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma","volume":"121","author":"Bang","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"34","doi-asserted-by":"crossref","first-page":"e76551","DOI":"10.1371\/journal.pone.0076551","article-title":"Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534)","volume":"8","author":"Khan","year":"2013","journal-title":"PLoS One"},{"issue":"18 Pt 1","key":"35","first-page":"6169","article-title":"The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression","volume":"10","author":"Ittmann","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"3","key":"36","first-page":"840","article-title":"Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele","volume":"62","author":"Bange","year":"2002","journal-title":"Cancer Res"},{"issue":"1","key":"37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.onc.1210623","article-title":"Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models","volume":"27","author":"French","year":"2008","journal-title":"Oncogene"},{"issue":"6","key":"38","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/liv.12462","article-title":"Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations","volume":"34","author":"Mellor","year":"2014","journal-title":"Liver international : official journal of the International Association for the Study of the Liver"},{"issue":"25","key":"39","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"40","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.humpath.2011.12.002","article-title":"Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma","volume":"43","author":"Kim","year":"2012","journal-title":"Hum Pathol"},{"issue":"10","key":"41","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1158\/1078-0432.CCR-06-2743","article-title":"AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2\/keratinocyte growth factor receptor","volume":"13","author":"Nishio","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7","key":"42","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ng2075","article-title":"A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer","volume":"39","author":"Hunter","year":"2007","journal-title":"Nat Genet"},{"issue":"2","key":"43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Grose","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"44","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1158\/0008-5472.CAN-13-3218","article-title":"Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC","volume":"74","author":"Wong","year":"2014","journal-title":"Cancer Res"},{"issue":"15","key":"45","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1158\/0008-5472.CAN-14-3771","article-title":"Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2","volume":"75","author":"Tanizaki","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/1541-7786.MCR-08-0021","article-title":"Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma","volume":"7","author":"Gartside","year":"2009","journal-title":"Mol Cancer Res"},{"issue":"4","key":"47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/CMR.0000000000000085","article-title":"Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment","volume":"24","author":"Chin","year":"2014","journal-title":"Melanoma Res"},{"issue":"1","key":"48","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4238\/2014.February.20.12","article-title":"Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis","volume":"13","author":"Yu","year":"2014","journal-title":"Genet Mol Res"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Couffignal, Desgrandchamps, Mongiat-Artus, Ravery, Ouzaid, Roupret, Phe, Ciofu, Tubach, Mentre, Cussenot, Grandchamp. The diagnostic and prognostic performance of urinary FGFR3 mutation analysis in bladder cancer surveillance: a prospective multicenter study. Urology. 2015.","DOI":"10.1016\/j.urology.2015.07.036"},{"issue":"1","key":"50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/12615","article-title":"Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas","volume":"23","author":"Radvanyi","year":"1999","journal-title":"Nat Genet"},{"issue":"3","key":"51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Bergsagel","year":"1997","journal-title":"Nat Genet"},{"issue":"6","key":"52","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/modpathol.2009.46","article-title":"FGFR3 mutations in prostate cancer: association with low-grade tumors","volume":"22","author":"Lloreta","year":"2009","journal-title":"Mod Pathol"},{"issue":"11","key":"53","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/ng.470","article-title":"Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors","volume":"41","author":"Wilkie","year":"2009","journal-title":"Nat Genet"},{"issue":"3","key":"54","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1078-0432.CCR-13-3310","article-title":"Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas","volume":"21","author":"Seiwert","year":"2015","journal-title":"Clin Cancer Res"},{"key":"55","doi-asserted-by":"crossref","unstructured":"von Massenhausen, et al. Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Target Oncol. 2016.","DOI":"10.1007\/s11523-016-0431-z"},{"issue":"8","key":"56","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1172\/JCI28163","article-title":"Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi","volume":"116","author":"Hartmann","year":"2006","journal-title":"J Clin Invest"},{"issue":"9","key":"57","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/hmg\/ddi127","article-title":"Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans","volume":"14","author":"Radvanyi","year":"2005","journal-title":"Hum Mol Genet"},{"key":"58","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Lengauer","year":"2014","journal-title":"Nat Commun"},{"issue":"4","key":"59","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: a review","volume":"41","author":"Miranda","year":"2010","journal-title":"Hum Pathol"},{"issue":"10","key":"60","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1182\/blood-2007-02-074286","article-title":"Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome","volume":"110","author":"Cross","year":"2007","journal-title":"Blood"},{"issue":"4","key":"61","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Shibata","year":"2014","journal-title":"Hepatology"},{"issue":"10","key":"62","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2005-10-4179","article-title":"The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells","volume":"107","author":"Yayon","year":"2006","journal-title":"Blood"},{"issue":"6099","key":"63","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming fusions of FGFR and TACC genes in human glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science"},{"key":"64","doi-asserted-by":"publisher","first-page":"55924","DOI":"10.18632\/oncotarget.10482","article-title":"FGFR3-TACC3 fusion in solid tumors: mini review","volume":"7","author":"Giles","year":"2016","journal-title":"Oncotarget"},{"issue":"24","key":"65","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-14-1337","article-title":"Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma","volume":"20","author":"Capelletti","year":"2014","journal-title":"Clin Cancer Res"},{"key":"66","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.gore.2015.06.005","article-title":"FGFR3-TACC3: A novel gene fusion in cervical cancer","volume":"13","author":"Johnson","year":"2015","journal-title":"Gynecol Oncol Rep"},{"issue":"8","key":"67","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm0897-887","article-title":"Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth","volume":"3","author":"Becker","year":"1997","journal-title":"Nat Med"},{"issue":"7","key":"68","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1541-7786.MCR-12-0652","article-title":"Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC","volume":"11","author":"Terai","year":"2013","journal-title":"Mol Cancer Res"},{"issue":"6","key":"69","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/pros.20728","article-title":"A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions","volume":"68","author":"Shitara","year":"2008","journal-title":"Prostate"},{"issue":"16","key":"70","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1158\/1078-0432.CCR-10-2727","article-title":"FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo","volume":"17","author":"Turner","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2011.03.015","article-title":"A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells","volume":"307","author":"Hirakawa","year":"2011","journal-title":"Cancer Lett"},{"issue":"4","key":"72","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/ijc.24763","article-title":"Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma","volume":"126","author":"Hirakawa","year":"2010","journal-title":"Int J Cancer"},{"issue":"3","key":"73","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: a further update","volume":"408","author":"Cohen","year":"2007","journal-title":"Biochem J"},{"issue":"6","key":"74","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2174\/187152011796011055","article-title":"Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma","volume":"11","author":"Lam","year":"2011","journal-title":"Anticancer Agents Med Chem"},{"issue":"13","key":"75","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer","volume":"19","author":"Andre","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"76","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","article-title":"CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma","volume":"105","author":"Stewart","year":"2005","journal-title":"Blood"},{"issue":"5","key":"77","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-12-2885","article-title":"Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma","volume":"19","author":"Escudier","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"11","key":"78","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-13-3006","article-title":"Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer","volume":"20","author":"Escudier","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"79","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","article-title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial","volume":"15","author":"Motzer","year":"2014","journal-title":"Lancet Oncol"},{"issue":"18","key":"80","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1016\/j.ejca.2014.10.013","article-title":"Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma","volume":"50","author":"Milowsky","year":"2014","journal-title":"Eur J Cancer"},{"issue":"3","key":"81","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Asada","year":"2008","journal-title":"Int J Cancer"},{"issue":"17","key":"82","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Asada","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"21","key":"83","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-14-3063","article-title":"Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma","volume":"21","author":"Hong","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"84","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/bjc.2013.374","article-title":"Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer","volume":"109","author":"Nishio","year":"2013","journal-title":"Br J Cancer"},{"issue":"8","key":"85","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Klinowska","year":"2012","journal-title":"Cancer Res"},{"issue":"9","key":"86","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1158\/1078-0432.CCR-12-3898","article-title":"FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547","volume":"19","author":"Xie","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"24","key":"87","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1158\/1078-0432.CCR-12-2694","article-title":"Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models","volume":"18","author":"Zhang","year":"2012","journal-title":"Clin Cancer Res"},{"key":"88","first-page":"5s","article-title":"A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data","volume":"32","author":"Kilgour","year":"2014","journal-title":"ASCO Annual Meeting J Clin Oncol"},{"key":"89","doi-asserted-by":"crossref","unstructured":"Hendrik-Tobias Arkenau, Hollebecque, Mathewson, Lemech, Landers, et al. A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer. 2014 ASCO Annual Meeting.","DOI":"10.1200\/jco.2014.32.15_suppl.2620"},{"key":"90","doi-asserted-by":"crossref","unstructured":"Smyth, et al. 2015. Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. 2015 ASCO Annual Meeting.","DOI":"10.1200\/jco.2015.33.15_suppl.2508"},{"issue":"20","key":"91","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6- [4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J Med Chem"},{"issue":"19 Supplement","key":"92","doi-asserted-by":"crossref","first-page":"CT326","DOI":"10.1158\/1538-7445.AM2014-CT326","article-title":"Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors","volume":"74","author":"Sequist","year":"2014","journal-title":"Cancer Res"},{"key":"93","first-page":"5s","article-title":"Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398","volume":"32","author":"Schuler","year":"2014","journal-title":"ASCO Annual Meeting J Clin Oncol"},{"issue":"19","key":"94","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1158\/1078-0432.CCR-14-3357","article-title":"FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers","volume":"21","author":"G\u00f6ke","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"95","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-13-3060","article-title":"FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies","volume":"20","author":"Wynes","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"96","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0050019","article-title":"Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting","volume":"5","author":"Hanahan","year":"2008","journal-title":"PLoS Med"},{"issue":"30","key":"97","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J Clin Oncol"},{"issue":"19","key":"98","doi-asserted-by":"crossref","first-page":"7630","DOI":"10.1158\/0008-5472.CAN-10-1489","article-title":"GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling","volume":"70","author":"Bai","year":"2010","journal-title":"Cancer Res"},{"key":"99","doi-asserted-by":"crossref","unstructured":"Sommer, et al. (2015 Apr 18-22). Preclinical anti-tumor efficacy of FGFR2-ADC BAY 1187982 in patient-derived gastric, breast and ovarian cancer models. 106th Annual AACR Meeting. Philadelphia, PA. Cancer Res. 2015; 75(15 Suppl). Abstract nr 1684.","DOI":"10.1158\/1538-7445.AM2015-1684"},{"issue":"17","key":"100","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1158\/1078-0432.CCR-05-0282","article-title":"Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation","volume":"11","author":"Casal","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"5","key":"101","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI38017","article-title":"Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice","volume":"119","author":"Qing","year":"2009","journal-title":"J Clin Invest"},{"issue":"Suppl 6","key":"102","first-page":"191","article-title":"A phase I dose-escalation study of MFGR1877S, a human monoclonal anti-fibroblast growth factor receptor 3 (FGFR3) antibody, in patients with advanced solid tumors","volume":"48","author":"Lu","year":"2012","journal-title":"Eru J Cancer"},{"key":"103","first-page":"5s","article-title":"Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors","volume":"32","author":"Zhong","year":"2014","journal-title":"ASCO 2014 Annual Meeting J Clin Oncol"},{"issue":"3","key":"104","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10555-015-9579-8","article-title":"Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications","volume":"34","author":"Kurzrock","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"105","unstructured":"2004. Drug Approval Package: Erbitux BLA 125084. FDA, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/bla\/2004\/125084_ERBITUX_PRNTLBL.PDF."},{"issue":"22","key":"106","doi-asserted-by":"crossref","first-page":"7022","DOI":"10.3748\/wjg.v21.i22.7022","article-title":"Standard chemotherapy with cetuximab for treatment of colorectal cancer","volume":"21","author":"Cai","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"5","key":"107","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/1758834015591952","article-title":"Precision medicine in colorectal cancer: the molecular profile alters treatment strategies","volume":"7","author":"Deming","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"108","volume-title":"Clinical Practice Guidlines in Oncology: Colon Cancer","author":"NCCN","year":"2014"},{"key":"109","doi-asserted-by":"crossref","unstructured":"Alorabi, Shonka, Ganti. EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role? Crit Rev Oncol Hematol. 2015.","DOI":"10.1016\/j.critrevonc.2015.12.006"},{"issue":"5","key":"110","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/annonc\/mdq588","article-title":"Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and\/or metastatic squamous cell carcinoma of the head and neck: EXTREME study","volume":"22","author":"Licitra","year":"2011","journal-title":"Ann Oncol"},{"issue":"21","key":"111","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/1078-0432.CCR-14-1190","article-title":"Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility","volume":"21","author":"Jeffrey","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12 Supplement 2","key":"112","first-page":"B4","article-title":"Abstract B4: Use of urinary circulating tumor DNA (ctDNA) KRAS for monitoring treatment response in patients with metastatic colorectal cancer (mCRC)","volume":"14","author":"Lenz","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"7404","key":"113","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"issue":"3","key":"114","first-page":"36","article-title":"Lung-MAP\u2014framework, overview, and design principles","volume":"4","author":"Papadimitrakopoulou","year":"2015","journal-title":"Chinese clinical oncology"},{"key":"115","doi-asserted-by":"crossref","unstructured":"NCI-MATCH Trial Draws Strong Interest. Cancer Discov. 2016; 6(4):334.","DOI":"10.1158\/2159-8290.CD-NB2016-018"},{"key":"116","unstructured":"Wang, Zhao, Zhang. The role of mutations and overexpression of the fibroblast growth factor receptor-3 in bladder cancer. Minerva Med. 2015."},{"key":"117","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/oncsis.2013.4","article-title":"A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop","volume":"2","author":"Heasley","year":"2013","journal-title":"Oncogenesis"},{"issue":"2","key":"118","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","article-title":"Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells","volume":"26","author":"Settleman","year":"2014","journal-title":"Cancer Cell"},{"issue":"7609","key":"119","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nature18600","article-title":"A combinatorial strategy for treating KRAS-mutant lung cancer","volume":"534","author":"Manchado","year":"2016","journal-title":"Nature"},{"issue":"4","key":"120","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Hanahan","year":"2005","journal-title":"Cancer Cell"},{"issue":"19","key":"121","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","article-title":"Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis","volume":"17","author":"Kopetz","year":"2011","journal-title":"Clin Cancer Res"},{"key":"122","doi-asserted-by":"crossref","first-page":"e1046","DOI":"10.1038\/cddis.2014.10","article-title":"Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer","volume":"5","author":"Johnston","year":"2014","journal-title":"Cell Death Dis"},{"issue":"5","key":"123","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res"},{"issue":"9","key":"124","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/2159-8290.CD-12-0569","article-title":"Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer","volume":"3","author":"Turner","year":"2013","journal-title":"Cancer Discov"},{"issue":"7","key":"125","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1038\/oncsis.2016.48","article-title":"Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy","volume":"5","author":"Kim","year":"2016","journal-title":"Oncogenesis"},{"issue":"6","key":"126","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Cortes","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"127","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ajh.24275","article-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","volume":"91","author":"Kantarjian","year":"2016","journal-title":"Am J Hematol"},{"key":"128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-016-0268-z","article-title":"Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer","volume":"9","author":"Liu","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"3","key":"129","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Varmus","year":"2005","journal-title":"PLoS Med"},{"issue":"8","key":"130","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Riely","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"131","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1053\/j.seminoncol.2015.09.028","article-title":"Overcoming Resistance to Targeted Therapies in Cancer","volume":"42","author":"Van Schaeybroeck","year":"2015","journal-title":"Semin Oncol"},{"key":"132","unstructured":"2015. Drug Approval Package: Tagrisso (osimertinib) tablet, for oral use In: FDA. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/208065s000lbl.pdf."},{"issue":"2","key":"133","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1753465815617871","article-title":"Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches","volume":"10","author":"Rangachari","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"134","unstructured":"2015. Alectinib (http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/208434s000lbl.pdf: FDA)."},{"issue":"45","key":"135","doi-asserted-by":"crossref","first-page":"E4869","DOI":"10.1073\/pnas.1403438111","article-title":"Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors","volume":"111","author":"Tan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"136","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/onc.2012.319","article-title":"Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance","volume":"32","author":"Cook","year":"2013","journal-title":"Oncogene"},{"issue":"5","key":"137","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1021\/acschembio.5b00014","article-title":"Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles\u2019 heel of targeted therapy","volume":"10","author":"Anderson","year":"2015","journal-title":"ACS Chem Biol"},{"issue":"17","key":"138","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/onc.2014.161","article-title":"Ligand-associated ERBB2\/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells","volume":"34","author":"Hammerman","year":"2015","journal-title":"Oncogene"},{"issue":"10","key":"139","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/1535-7163.MCT-12-0511","article-title":"Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification","volume":"11","author":"Arteaga","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"140","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1053\/j.seminoncol.2015.09.027","article-title":"Fibroblast Growth Factor (FGF) Receptor\/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors","volume":"42","author":"Tabernero","year":"2015","journal-title":"Semin Oncol"},{"key":"141","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.critrevonc.2015.10.021","article-title":"Novel therapeutic targets in advanced urothelial carcinoma","volume":"98","author":"Soria","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"142","doi-asserted-by":"crossref","unstructured":"Hahn, et al. Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression. Hoosier Cancer Research Network. GU12-157. 2016 ASCO Annual Meeting. Chicago, IL. J Clin Oncol. 34. 2016. (suppl; abstr 4526).","DOI":"10.1200\/JCO.2016.34.15_suppl.4526"},{"key":"143","doi-asserted-by":"crossref","unstructured":"EVC, Mansoor, Petty Russell, Chao, Cunningham, Ferry, Landers, Stockman, Smith Neil, Geh, Kilgour; A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study 2015 ASCO Annual Meeting (Chicago, IL). J Clin Oncol. 33, 2015 (suppl; abstr 4014).","DOI":"10.1200\/jco.2015.33.15_suppl.4014"},{"key":"144","doi-asserted-by":"crossref","unstructured":"Pal, et al. Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced\/metastatic urothelial carcinoma (mUC) with FGFR3 alterations. 2016 ASCO Annual Meeting. Chicago, IL. J Clin Oncol. 34. 2016. (suppl; abstr 4517).","DOI":"10.1200\/JCO.2016.34.15_suppl.4517"},{"key":"145","article-title":"A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy","volume":"34","author":"Javle","journal-title":"J Clin Oncol"},{"key":"146","volume-title":"J Clin Oncol","volume":"34","author":"Garc\u00eda-Donas","year":"2016"},{"key":"147","volume-title":"J Clin Oncol","volume":"34","author":"Hyman","year":"2016"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T09:01:05Z","timestamp":1718960465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,22]]},"references-count":147,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,2,28]]}},"alternative-id":["14109","28030802"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.14109","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,22]]}}}